13F filer · CIK 1544773
Consonance Capital Management LP
New York, NY · filing since Q2 2013 · last filing Nov 14, 2022
Reported value
$7.3M
$-16.4M vs prior
Positions
2
New / sold out
0 / 5
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $13.0M
Top-10 weight
100.0%
Biggest buys vs Q2 2022
No new or increased positions this quarter.
Biggest sells vs Q2 2022
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SILENCE THERAPEUTICS PLC | -634,270 | -100.0% | $-7.5M |
| Sold out | COMPASS THERAPEUTICS INC | -1,603,789 | -100.0% | $-4.2M |
| Sold out | UNITED THERAPEUTICS CORP DEL | -2,998 | -100.0% | $-706.0K |
| Sold out | GLOBUS MED INC | -5,405 | -100.0% | $-303.0K |
| Sold out | TANDEM DIABETES CARE INC | -4,294 | -100.0% | $-254.0K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2022
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | SURROZEN INCCOM | 3,497,500 | $7.1M | 97.05% |
| 2 | SURROZEN INC*W EXP 08/01/203 | 1,165,832 | $215.0K | 2.95% |